IL262709B - Precipitation sensor - Google Patents
Precipitation sensorInfo
- Publication number
- IL262709B IL262709B IL262709A IL26270918A IL262709B IL 262709 B IL262709 B IL 262709B IL 262709 A IL262709 A IL 262709A IL 26270918 A IL26270918 A IL 26270918A IL 262709 B IL262709 B IL 262709B
- Authority
- IL
- Israel
- Prior art keywords
- substrate
- modified
- group
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60S—SERVICING, CLEANING, REPAIRING, SUPPORTING, LIFTING, OR MANOEUVRING OF VEHICLES, NOT OTHERWISE PROVIDED FOR
- B60S1/00—Cleaning of vehicles
- B60S1/02—Cleaning windscreens, windows or optical devices
- B60S1/04—Wipers or the like, e.g. scrapers
- B60S1/06—Wipers or the like, e.g. scrapers characterised by the drive
- B60S1/08—Wipers or the like, e.g. scrapers characterised by the drive electrically driven
- B60S1/0818—Wipers or the like, e.g. scrapers characterised by the drive electrically driven including control systems responsive to external conditions, e.g. by detection of moisture, dirt or the like
- B60S1/0822—Wipers or the like, e.g. scrapers characterised by the drive electrically driven including control systems responsive to external conditions, e.g. by detection of moisture, dirt or the like characterized by the arrangement or type of detection means
- B60S1/0825—Capacitive rain sensor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60S—SERVICING, CLEANING, REPAIRING, SUPPORTING, LIFTING, OR MANOEUVRING OF VEHICLES, NOT OTHERWISE PROVIDED FOR
- B60S1/00—Cleaning of vehicles
- B60S1/02—Cleaning windscreens, windows or optical devices
- B60S1/04—Wipers or the like, e.g. scrapers
- B60S1/06—Wipers or the like, e.g. scrapers characterised by the drive
- B60S1/08—Wipers or the like, e.g. scrapers characterised by the drive electrically driven
- B60S1/0818—Wipers or the like, e.g. scrapers characterised by the drive electrically driven including control systems responsive to external conditions, e.g. by detection of moisture, dirt or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60S—SERVICING, CLEANING, REPAIRING, SUPPORTING, LIFTING, OR MANOEUVRING OF VEHICLES, NOT OTHERWISE PROVIDED FOR
- B60S1/00—Cleaning of vehicles
- B60S1/02—Cleaning windscreens, windows or optical devices
- B60S1/04—Wipers or the like, e.g. scrapers
- B60S1/06—Wipers or the like, e.g. scrapers characterised by the drive
- B60S1/08—Wipers or the like, e.g. scrapers characterised by the drive electrically driven
- B60S1/0818—Wipers or the like, e.g. scrapers characterised by the drive electrically driven including control systems responsive to external conditions, e.g. by detection of moisture, dirt or the like
- B60S1/0822—Wipers or the like, e.g. scrapers characterised by the drive electrically driven including control systems responsive to external conditions, e.g. by detection of moisture, dirt or the like characterized by the arrangement or type of detection means
- B60S1/0874—Wipers or the like, e.g. scrapers characterised by the drive electrically driven including control systems responsive to external conditions, e.g. by detection of moisture, dirt or the like characterized by the arrangement or type of detection means characterized by the position of the sensor on the windshield
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/22—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Automation & Control Theory (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Glass Compositions (AREA)
Description
FIELD AND BACKGROUND OF THE INVENTION We Claim 1. A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 is -C(1-6)alkyl or -C(0-3)alkylC(3-6)cycloalkyl; wherein the -C(1-6)alkyl and the -C(0-3)alkylC(3-6)cycloalkyl are unsubstituted or substituted with one to six fluorine atoms; R2 is -C(3-5)cycloalkyl; R3 is -C(0-1)alkylC(3-6)cycloalkyl, wherein the -C(0-1)alkylC(3-6)cycloalkyl is unsubstituted or substituted with one to five fluorine atoms; R4 is -C(3-4)cycloalkyl or a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the C(3-4)cycloalkyl is unsubstituted or substituted with one to three R4a groups; and wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4b groups; each R4a group is independently selected from -C(1-4)alkyl that is unsubstituted or substituted with one to six fluorine atoms; and each R4b group is independently selected from -C(0-2)alkylC(3-4)cycloalkyl or -C(1-5)alkyl, wherein the -C(0-2)alkylC(3-4)cycloalkyl and -C(1-5)alkyl are unsubstituted or substituted with one to six fluorine atoms; R5 is H or F; wherein when R4 is -C(3-4)cycloalkyl then the compound of Formula I is a compound of Formula la: 139 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: R1 is -C(1-6)alkyl or -C(0-3)alkylC(3-6)cycloalkyl; wherein the -C(1-6)alkyl and the -C(0-3)alkylC(3-6)cycloalkyl are unsubstituted or substituted with one to six fluorine atoms; R2 is -C(3-5)cycloalkyl; R3 is -C(0-1)alkylC(3-6)cycloalkyl, wherein the -C(0-1)alkylC(3-6)cycloalkyl is unsubstituted or substituted with one to five fluorine atoms; R4 is a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4b groups; each R4b group is independently selected from -C(0-2)alkylC(3-4)cycloalkyl or -C(1-5)alkyl, wherein the -C(0-2)alkylC(3-4)cycloalkyl and -C(1-5)alkyl are unsubstituted or substituted with one to six fluorine atoms; and R5 is H or F. 3. The compound of claims 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: R5 is H. 4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein: R1 is -C(1-4)alkyl or -C(0-3)alkylC(3-5)cycloalkyl; wherein the -C(1-4)alkyl and the -C(0-3)alkylC(3-5)cycloalkyl are unsubstituted or substituted with one to six fluorine atoms.
. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein: 140 R1 is -C(1-3)alkyl or -C(0-3)alkylC(3-5)cycloalkyl; wherein the -C(1-3)alkyl and the -C(0-3)alkylC(3-5)cycloalkyl are unsubstituted or substituted with one to six fluorine atoms. 6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein: R1 is -C(1-3)alkyl, wherein the -C(1-3)alkyl is unsubstituted or substituted with one to three fluorine atoms. 7. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein: R1 is C(0-3)alkylC(3-5)cycloalkyl, wherein the -C(0-3)alkylC(3-5)cycloalkyl is unsubstituted or substituted with one to six fluorine atoms. 8. The compound of any one of claims 1 to 5 and 7, or a pharmaceutically acceptable salt thereof, wherein: R1 is C(1-2)alkylC(3-5)cycloalkyl, wherein the -C(1-2)alkylC(3-5)cycloalkyl is unsubstituted or substituted with one to three fluorine atoms. 9. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R1 is: CH3 . The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R1 is: is: 141 F 11. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R2 is -C(3-4)cycloalkyl. 12. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R2 is cyclopropyl. 13. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R3 is -C(0)alkylC(5-6)cycloalkyl, wherein the -C(0)alkylC(5-6)cycloalkyl is unsubstituted or substituted with one to five fluorine atoms. 14. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R3 is -C(0)alkylC(5-6)cycloalkyl, wherein the -C(0)alkylC(5-6)cycloalkyl is unsubstituted or substituted with one to three fluorine atoms.
. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R3 is -C(0)alkylC(6)cycloalkyl, wherein the -C(0)alkylC(6)cycloalkyl is unsubstituted or substituted with one to two fluorine atoms. 142 16. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein ؛ /—\ F R3 is ' F. 17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R4 is a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N and O; wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R4b groups; each R4b group is independently selected from -C(0-1)alkylC(3)cycloalkyl or -C(1-3)alkyl, wherein the -C(0-1)alkylC(3)cycloalkyl and -C(1-3)alkyl are unsubstituted or substituted with one to four fluorine atoms. 18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein R4 is pyridinyl that is unsubstituted or substituted with C(1-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms. 19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, ״Y^^GF3 wherein wherein R4 is . The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein R4 is pyrazolyl, triazolyl, isoxazolyl, or oxadiazolyl that is unsubstituted or substituted with one or two R4b groups, each R4b group is independently selected from -C(0-1)alkylC(3)cycloalkyl or -C(1-3)alkyl, wherein the -C(0-1)alkylC(3)cycloalkyl and -C(1-3)alkyl are unsubstituted or substituted with one to four fluorine atoms. 143 21. The compound of any one of claims 1 to 17 and 20, or a pharmaceutically acceptable salt thereof, wherein R4 is pyrazolyl, triazolyl, isoxazolyl, or oxadiazolyl that is unsubstituted or substituted with one or two R4b groups, each R4b group is independently selected from -C(1)alkylC(3)cycloalkyl or -C(1-3)alkyl, wherein the -C(1)alkylC(3)cycloalkyl and -C(1-3)alkyl are unsubstituted or substituted with one to three fluorine atoms. 22. The compound of any one of claims 1 to 17, 20 and 21, or a pharmaceutically acceptable salt thereof, wherein R4 is pyrazolyl, triazolyl, isoxazolyl, or oxadiazolyl that is unsubstituted or substituted with one or two R4b groups, each R4b group is independently -C(1-3)alkyl, wherein the -C(1-3)alkyl is unsubstituted or substituted with one to three fluorine atoms. 23. The compound of any one of claims 1 to 17 and 20 to 22, or a pharmaceutically acceptable salt thereof, wherein R4 is 1H-pyrazolyl , 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 177-1,2,4- triazolyl, isoxazole-4-yl, or 1,2,5-oxadiazolyl that is unsubstituted or substituted with one or two R4b groups. 24. The compound of any one of claims 1 to 17 and 20 to 23, or a pharmaceutically acceptable salt thereof, wherein R4 is 1H-pyrazolyl , 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 177-1,2,4- triazolyl, isoxazole-4-yl, isoxazole-3-yl, or 1,2,5-oxadiazolyl that is unsubstituted or substituted with one or two R4b groups.
. The compound of any one of claims 1 to 17 and 20 to 23, or a pharmaceutically acceptable salt thereof, wherein R4 is 177-pyrazol-3-yl, 177-pyrazol-4-yl, lH-pyrazol-5-yl, 177-1,2,3-triazol- -yl, 277-l,2,3-triazol-4-yl, 177-l,2,4-triazol-5-yl, isoxazole-4-yl, or 1,2,5-oxadiazol-3-yl that is unsubstituted or substituted with one or two R4b groups. 26. The compound of any one of claims 1 to 17 and 20 to 25, or a pharmaceutically acceptable salt thereof, wherein R4 is 177-pyrazol-3-yl, 177-pyrazol-4-yl, lH-pyrazol-5-yl, 177-1,2,3-triazol- 144 -yl, 2/f-l,2,3-triazol-4-yl, l/f-l,2,4-triazol-5-yl, isoxazole-4-yl, isoxazole-3-yl or 1,2,5- oxadiazol-3-yl that is unsubstituted or substituted with one or two R4b groups. 27. The compound of any one of claims 1 to 17,20 to 23 and 25 or a pharmaceutically acceptable salt thereof, wherein R4 is: 28. The compound of any one of claims 1 to 17, and 20 to 26 or a pharmaceutically acceptable salt thereof, wherein R4 is 145 29. The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R4 is: . The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R4 is: 31. The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R4 is: 146 32. The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R4 is: 33. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein: R4 is -C(3)cycloalkyl; wherein the C(3)cycloalkyl is unsubstituted or substituted with one to three R4a groups; and each R4a group is independently selected from -C(1-2)alkyl that is unsubstituted or substituted with one to three fluorine atoms; and wherein the compound of Formula I is a compound of Formula la: 34. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds in Table 1A, Table 1AA and Table IB.
. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from 147 148 149 150 151 36. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from 152 153 154 155 156 157 158 37. The compound of claim 35 or 36, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from 159 38. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is 39. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is 40. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is 41. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is 160 43. A pharmaceutical composition, comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 44. A pharmaceutical composition made by mixing a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 45. The pharmaceutical composition of claim 43 or 44, which is administered orally. 46. The pharmaceutical composition of claim 45, which is administered as a tablet or a capsule. 47. A process for making a pharmaceutical composition comprising mixing a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 48. A method for treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically 161 effective amount of a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof. 49. The method of claim 48, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigoid, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus. 50. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriasis. 51. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriatic arthritis. 52. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is rheumatoid arthritis. 53. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is ankylosing spondylitis. 54. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is hidradenitis suppurativa. 55. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is bullous pemphigoid. 56. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is atopic dermatitis. 162 57. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is vitiligo. 58. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple sclerosis. 59. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus. 60. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is asthma. 61. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is uveitits. 62. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is chronic obstructive pulmonary disorder. 63. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple myeloma. 64. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus. 65. The method of any of claims 48 to 64, wherein the compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, is administered orally. 66. The method of any of claims 48 to 65, wherein the compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, is administered as a tablet or a capsule. 163 67. A compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for use in treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease. 68. A compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for use in medical therapy. 69. The use of a compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease. 70. The use of a compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease. 71. A compound or method as described herein. 164 DynamicPDF for .NET v8.0.0.40 (Build 29393)
Claims (24)
1. A substrate comprising: (c) keratin derivative; and (d) natural biopolymer, wherein the keratin derivative and natural biopolymer are crosslinked.
2. The substrate of claim 1, wherein the keratin derivative is selected from the group consisting of keratin intermediate filament protein, kerateine, keratose, and combinations thereof.
3. The substrate of claim 1 or 2, wherein the keratin derivative is derived from any human and/or animal source selected from the group consisting of hair, nail, wool, fur, horn, hoof, feather, scales, and combinations thereof.
4. The substrate of any one of the preceding claims, wherein the natural biopolymer is a modified natural biopolymer.
5. The substrate of any one of the preceding claims, wherein the natural biopolymer or modified natural biopolymer comprises hydroxyl, amine, carboxyl, thiol, aldehyde, and/or methacrylate groups.
6. The substrate of any one of the preceding claims, wherein the natural biopolymer is selected from the group consisting of cellulose, modified cellulose, nanocellulose, modified nanocellulose, chitosan, modified chitosan, chitin, modified chitin, collagen, modified collagen, fibrinogen, modified fibrinogen, polysaccharide, modified polysaccharide, starch, modified starch, alginate, modified alginate, silk fibroin, modified silk fibroin, sericin, modified sericin, pullulan, modified pullulan, and combinations thereof.
7. The substrate of claim 6, wherein the nanocellulose is selected from the group consisting of cellulose nanocrystals, modified cellulose nanocrystals, cellulose nanofibrils, modified cellulose nanofibrils, bacterial nanocellulose, and modified bacterial nanocellulose.
8. The substrate of any one of the preceding claims, wherein the molecular weight of the keratin derivative is about 40 kDa to about 60 kDa.
9. The substrate of any one of the preceding claims, comprising about 0.5 wt% to about 2.0 wt% keratin derivative, based on the total weight of the substrate.
10. The substrate of any one of the preceding claims, comprising about 0.25 wt% to about 1.0 wt% natural biopolymer, based on the total weight of the substrate.
11. The substrate of any one of the preceding claims, wherein the weight percentage ratio of keratin derivative to natural biopolymer is about 5:1 to about 5:3. 27
12. The substrate of any one of the preceding claims, wherein the substrate further comprises: (c) micronutrients, macronutrients, pesticides and/or bioactives.
13. The substrate of claim 12, wherein the micronutrient is selected from the group consisting of metal oxides, metal salts, silica, carbon dots, and combinations thereof.
14. The substrate according to claim 12, wherein the bioactive is selected from the group consisting of biomolecules, antimicrobial agents, omega 3, folic acid, boron and calcium.
15. The substrate of claim 13, wherein the metal is selected from the group consisting of zinc, copper, iron, magnesium, manganese, titanium, molybdenum, cobalt, nickel, silver, gold and combinations thereof.
16. The substrate of any one of claims 12-14, wherein the micronutrients are particulates with an average diameter of about 1 nm to about 500 nm.
17. The substrate of any one of claims 12-15, wherein the concentration of the micronutrient, pesticide or bioactive, when present, in the substrate is independently about 0.005 mg/ml to about 1.0 mg/ml, and the concentration of the macronutrient, when present, in the substrate is about 1 mg/ml to about 50 mg/ml .
18. The substrate of any one of the preceding claims, wherein the substrate has a pore size of about 100 µm to about 200 µm.
19. The substrate according to anyone of the preceding claims, wherein the substrate comprises: (i) keratin intermediate filament protein; (ii) cellulose nanofibrils; and (iii) particulate micronutrients selected from the group consisting of metal oxides, metal salts, silica, carbon dots, and combinations thereof, wherein the metal is selected from the group consisting of zinc, copper, iron, magnesium manganese, titanium, molybdenum, cobalt, nickel, silver, gold and combinations thereof.
20. A method of forming a substrate of any one of the preceding claims, wherein the method comprises: (i) mixing a solution of keratin derivative with a solution of natural biopolymer; and (ii) drying the resulting solution of step (i) to obtain the substrate.
21. The method of claim 20, further comprising step (i') dispersing micronutrients, macronutrients, pesticides, and/or bioactives, into the solution of keratin derivative, wherein step (i') occurs before step (i). 28
22. The method of claim 20 or 21, wherein step (ii) comprises drying the resulting solution for at least 24 hours.
23. The method of any one of claims 20-22, wherein step (ii) comprises freeze drying the solution of step (i) at a temperature of about -10oC to about -80oC.
24. Use of a substrate of any one of claims 1-19 as a plant growth medium or a hydroponic support medium. Dr. Gitay Kryger Patent Attorney G.E. Ehrlich (1995) Ltd. 35 HaMasger Street Sky Tower, 13th Floor Tel Aviv 6721407
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL262709A IL262709B2 (en) | 2018-10-31 | 2018-10-31 | Precipitation sensor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL262709A IL262709B2 (en) | 2018-10-31 | 2018-10-31 | Precipitation sensor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL262709A IL262709A (en) | 2020-04-30 |
| IL262709B true IL262709B (en) | 2022-12-01 |
| IL262709B2 IL262709B2 (en) | 2023-04-01 |
Family
ID=65910826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL262709A IL262709B2 (en) | 2018-10-31 | 2018-10-31 | Precipitation sensor |
Country Status (1)
| Country | Link |
|---|---|
| IL (1) | IL262709B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668478A (en) * | 1995-05-15 | 1997-09-16 | Itt Automotive Electrical Systems, Inc. | Windshield rain sensor |
| US20070200718A1 (en) * | 2006-01-10 | 2007-08-30 | Guardian Industries Corp. | Rain sensor with selectively reconfigurable fractal based sensors/capacitors |
-
2018
- 2018-10-31 IL IL262709A patent/IL262709B2/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668478A (en) * | 1995-05-15 | 1997-09-16 | Itt Automotive Electrical Systems, Inc. | Windshield rain sensor |
| US20070200718A1 (en) * | 2006-01-10 | 2007-08-30 | Guardian Industries Corp. | Rain sensor with selectively reconfigurable fractal based sensors/capacitors |
Also Published As
| Publication number | Publication date |
|---|---|
| IL262709B2 (en) | 2023-04-01 |
| IL262709A (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jao et al. | Protein-based drug-delivery materials | |
| JP6768528B2 (en) | Sustained release fertilizer containing oxidized glutathione | |
| Popa et al. | Bacterial cellulose—a remarkable polymer as a source for biomaterials tailoring | |
| Bao et al. | Functionalization and antibacterial applications of cellulose-based composite hydrogels | |
| CN109169702A (en) | Nanosizing RNAi preparation and its preparation method and application | |
| Ianchis et al. | Hydrogel-clay nanocomposites as carriers for controlled release | |
| Gheorghiță et al. | Chitosan-Based Biomaterials for Hemostatic Applications: A Review of Recent Advances | |
| Tudora et al. | Natural silk fibroin micro-and nanoparticles with potential uses in drug delivery systems | |
| CN101862469A (en) | Chitosan derivative quick hemostasis granules and preparation method thereof | |
| Shagdarova et al. | Collagen/chitosan gels cross-linked with genipin for wound healing in mice with induced diabetes | |
| Azman et al. | Novel Dioscorea hispida starch-based hydrogels and their beneficial use as disinfectants | |
| JP5908496B2 (en) | Method for extracting human serum albumin from the grain of transgenic rice | |
| IL262709B (en) | Precipitation sensor | |
| CN102558391A (en) | Vitamin E succinate-chitosan graft and preparation method and application thereof | |
| Li et al. | Progress in the preparation of stimulus-responsive cellulose hydrogels and their application in slow-release fertilizers | |
| Madivoli | Polysaccharide based hydrogels in drug delivery systems, wound healing, and agriculture | |
| Tyeb et al. | Polysaccharide based transdermal patches for chronic wound healing: Recent advances and clinical perspective | |
| CN106674838A (en) | Degradable garlic-oil-containing bentonite/PVA (polyvinyl alcohol) bactericidal preservative film and preparation method thereof | |
| Tong et al. | Design and evaluation of chitosan-amino acid thermosensitive hydrogel | |
| CN110950970B (en) | Environment-responsive glucosyl nanoparticles and processing method thereof | |
| CN111281980A (en) | Water-soluble gamma-polyglutamic acid-tilmicosin compound and preparation method thereof | |
| JPS61500067A (en) | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid or its metal salt and sulfur | |
| RU2586697C1 (en) | Method of producing chitosan-based films using ion cross-linking reagents | |
| CN101239180B (en) | Complexes for target killing tumor cell, preparation and application thereof | |
| CN113896786B (en) | Artificial synthetic material with biological activity and agricultural application thereof |